EA202092472A1 - Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности - Google Patents
Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхностиInfo
- Publication number
- EA202092472A1 EA202092472A1 EA202092472A EA202092472A EA202092472A1 EA 202092472 A1 EA202092472 A1 EA 202092472A1 EA 202092472 A EA202092472 A EA 202092472A EA 202092472 A EA202092472 A EA 202092472A EA 202092472 A1 EA202092472 A1 EA 202092472A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hyaluronic acid
- prevention
- ocular surface
- treatment
- severe disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Данное изобретение касается способа ослабления, предупреждения или отсрочивания начала тяжелого заболевания глазной поверхности, или предупреждения или задержки развития заболевания глазной поверхности легкой или умеренной степени до тяжелого заболевания глазной поверхности посредством местного введения жидкости, содержащей высокомолекулярную гиалуроновую кислоту, на глазную поверхность глаза человеческого субъекта или животного субъекта, не являющегося человеком, где данная гиалуроновая кислота имеет характеристическую вязкость больше 2,5 м3/кг и концентрацию меньше 0,2% мас./об.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862659215P | 2018-04-18 | 2018-04-18 | |
PCT/EP2019/059965 WO2019202017A1 (en) | 2018-04-18 | 2019-04-17 | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092472A1 true EA202092472A1 (ru) | 2021-03-25 |
Family
ID=66223746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092472A EA202092472A1 (ru) | 2018-04-18 | 2019-04-17 | Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210077523A1 (ru) |
EP (1) | EP3781175A1 (ru) |
CN (1) | CN112292135A (ru) |
CA (1) | CA3097478A1 (ru) |
EA (1) | EA202092472A1 (ru) |
WO (1) | WO2019202017A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202000015583A1 (it) * | 2020-06-30 | 2021-12-30 | Iromed Group S R L | Composizione oftalmica |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5492936A (en) * | 1990-11-30 | 1996-02-20 | Allergan, Inc. | Bimodal molecular weight hyaluronate formulations and methods for using same |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE10161110A1 (de) * | 2001-12-12 | 2003-06-26 | Ursapharm Arzneimittel Gmbh | Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung |
GB0130603D0 (en) * | 2001-12-20 | 2002-02-06 | Renaissance Healthcare Europ L | Improvements in or relating to ophthalmic solutions |
DE102005055275A1 (de) * | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
US20170014339A1 (en) * | 2015-07-17 | 2017-01-19 | i.com medical GmbH | Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute |
EP3871682A1 (en) * | 2016-10-14 | 2021-09-01 | i.com Medical GmbH | Method for establishing, restoring, and preserving homeostasis of the ocular surface |
-
2019
- 2019-04-17 WO PCT/EP2019/059965 patent/WO2019202017A1/en unknown
- 2019-04-17 CA CA3097478A patent/CA3097478A1/en active Pending
- 2019-04-17 US US17/048,451 patent/US20210077523A1/en active Pending
- 2019-04-17 EA EA202092472A patent/EA202092472A1/ru unknown
- 2019-04-17 EP EP19718363.5A patent/EP3781175A1/en not_active Withdrawn
- 2019-04-17 CN CN201980040490.9A patent/CN112292135A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3781175A1 (en) | 2021-02-24 |
CN112292135A (zh) | 2021-01-29 |
CA3097478A1 (en) | 2019-10-24 |
US20210077523A1 (en) | 2021-03-18 |
WO2019202017A1 (en) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
RU2017115563A (ru) | Композиции и способы лечения дисфункции мейбомиевых желез | |
MD3774791T2 (ro) | Compuși heterociclici ca imunomodulatori | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
RU2020123728A (ru) | Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения | |
JOP20190008A1 (ar) | علاج ومنع اضطرابات النوم | |
EA202190073A1 (ru) | Композиции и способы лечения видов гемоглобинопатии и талассемии | |
MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
WO2020081879A3 (en) | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | |
WO2019169333A8 (en) | Afibrotic compounds, devices, and uses thereof | |
EA202091396A1 (ru) | Композиции и способы лечения метаболических состояний | |
MX2022013650A (es) | Imidazopirimidinas como moduladores de il-17. | |
MX2022007285A (es) | Compuestos, polimeros, dispositivos y usos de los mismos. | |
MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
EA202092472A1 (ru) | Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности | |
MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
MX2018008272A (es) | Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos. | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MX2022011697A (es) | Inhibidores de ciclofilina y usos de los mismos. | |
EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
EA202192047A1 (ru) | Соединения и их применение | |
EA202092691A1 (ru) | Соединения для устранения боли, композиции, содержащие их, и способы их применения | |
BR112017025189A2 (pt) | composição e usos da mesma |